| Company Name: | Abiomed, Inc. | | Ticker Symbol: | ABMD | | | WWW Address: | www.abiomed.com |
| CEO: | Mr. Michael R. Minogue | | No. of Employees: | 374 |
| Common Issue Type: | CS | | Business Description: | Abiomed, Inc. is a provider of medical devices in circulatory support and it offers a continuum of care in heart recovery to acute heart failure patients. Its products are designed to enable the heart to rest, heal and recover by improving blood flow.
|
| | | Industry Information: | HEALTH SERVICES - Medical Appliances & Equipment [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 21.99 |  0.27 | 20.44 | 40.0 | 21.72 | 21.78 | 21.39 | 339568 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 847.9 | 38.6 | 1.27 | 0.37 | 0.00 | 58.7 | 0.0 | 24.93 - 11.80 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 21.72 | $ | | PE Ratio - LTM | 58.7 | |
| Market Capitalisation | 847.9 | mil |
| Latest Shares Outstanding | 38.6 | mil |
| Earnings pS (EPS) | 0.37 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 31.6 | mil |
| Float as % of Shares Outstanding | 80.1 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 52.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 17.20 | % |
| Gross Profit Margin | 82.4 | % |
| EBITDA Margin | 12.3 | % |
| Pre-Tax Profit Margin | 10.3 | % |
| Assets Turnover | 1.0 | % |
| Return on Assets (ROA) | 8.4 | % |
| Return on Equity (ROE) | 10.2 | % |
| Return on Capital Invested (ROCI) | 10.2 | % |
| Current Ratio | 5.2 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 2.56 | $ |
| Cash pS | 0.28 | $ |
| Book-Value pS | 3.53 | $ |
| Tangible Book-Value pS | 2.58 | $ |
| Cash Flow pS | 0.45 | $ |
| Free Cash Flow pS | 0.57 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 6.16 | |
| Price/Tangible Book Ratio | 8.41 | |
| Price/Cash Flow | 48.8 | |
| Price/Free Cash Flow | 38.1 | |
| P/E as % of Industry Group | 278.0 | % |
| P/E as % of Sector Segment | 213.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -6.9 | 94 | 4,986 | 17,653 |
| 4 Weeks | 23.50 | 17.74 | 17.96 | 20.9 | 116 | 4,794 | 91,093 |
| 13 Weeks | 23.50 | 14.70 | 14.72 | 47.6 | 135 | 4,643 | 292,487 |
| 26 Weeks | 23.50 | 11.80 | 14.25 | 52.4 | 130 | 6,790 | 841,995 |
| 52 Weeks | 24.93 | 11.80 | 20.80 | 4.4 | 83 | 6,452 | 1,600,139 |
| YTD | 23.50 | 11.96 | - | 61.6 | 140 | 5,578 | 552,237 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 22.59 | 22.82 | 19.02 | 15.76 | 17.31 | 1.27 | 1.75 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 21.23 | 99.6 | 22.87 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 0.00 |
| R&D | 1.92 | NA | 0.81 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 25.1 | 17.0 | 24.9 |
| Earnings % | 904.3 | 45.8 | 904.3 |
| EPS % | 825.0 | 42.9 | 825.0 |
| EPS $ | 0.33 | 0.03 | 0.33 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 52.68 |
| Current Ratio | 4.3 |
| Quick Ratio (Acid Test) | 3.7 |
| Liquidity Ratio (Cash) | 2.84 |
| Receivables Turnover | 7.3 |
| Average Collection Period | 49 |
| Working Capital/Equity | 65.3 |
| Working Capital pS | 2.32 |
| Cash-Flow pS | 0.00 |
| Free Cash-Flow pS | 0.00 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 17.12 |
| Financial Leverage Ratio (Assets/Equity) | 1.2 |
| Debt Ratio | 19.4 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 4.3 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 15.02 |
| Tobin's Q Ratio | 4.93 |
| Current P/E Ratio - LTM | 58.70 |
| Enterprise Value (EV)/EBITDA | 47.66 |
| Enterprise Value (EV)/Free Cash Flow | 0.00 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 8.41 |
| Price/Book Ratio - LTM | 6.16 |
| Price/Cash Flow Ratio | 48.8 |
| Price/Free Cash Flow Ratio - LTM | 38.1 |
| Price/Sales Ratio | 5.30 |
| P/E Ratio (1 month ago) - LTM | 48.5 |
| P/E Ratio (26 weeks ago) - LTM | 40.7 |
| P/E Ratio (52 weeks ago) - LTM | 520.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 278.0 |
| P/E as % of Sector Segment | 213.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 62.1 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.70 |
| Tangible Book Value pS - LTM | 2.58 |
| Book Value pS - LTM | 3.53 |
| Capital Invested pS | 3.56 |
| Cash pS - LTM | 0.28 |
| Cash Flow pS - LTM | 0.45 |
| Free Cash Flow pS - LTM | 0.57 |
| Earnings pS (EPS) | 0.37 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 0.00 |
| Free Cash Flow Margin 5YEAR AVG | -6.83 |
| Net Profit Margin | 9.5 |
| Net Profit Margin - 5YEAR AVRG. | -8.6 |
| Equity Productivity | 1.15 |
| Return on Equity (ROE) | 11.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 1.15 |
| Return on Capital Invested (ROCI) | 11.0 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -18.6 |
| Assets Productivity | 1.00 |
| Return on Assets (ROA) | 8.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | -15.2 |
| Gross Profit Margin | 82.4 |
| Gross Profit Margin - 5YEAR AVRG. | 80.3 |
| EBITDA Margin - LTM | 12.3 |
| EBIT Margin - LTM | 10.3 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -22.0 |
| Effective Tax Rate | 11.0 |
| Effective Tax Rate - 5YEAR AVRG. | 7.6 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 52 |
| Revenue per Employee | |
| Net Income per Employee | |
| Average Collection Period | 52 |
| Receivables Turnover | 7.3 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 9.4 |
| Accounts Payble/Sales | 4.87 |
| Assets/Revenue | 1.00 |
| Net Working Capital Turnover | 1.77 |
| Fixed Assets Turnover | 2.96 |
| Total Assets Turnover | 1.0 |
| Revenue per $ Cash | 16.73 |
| Revenue per $ Plant | 24.14 |
| Revenue per $ Common Equity | 1.15 |
| Revenue per $ Capital Invested | 1.15 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 68.0 |
| Research & Devlopment (R&D) as % of Revenue | 0.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
|
|  
|
| |
 |  |
